INO Quote, Trading Chart, Inovio Pharmaceuticals Inc.
$11.10 Last:
-3.39% Change Percent:
$11.56 Open:
$11.10 Previous Close:
$11.848 High:
$10.85 Low:
12,176,569 Volume:
02/26/2021 04:55:40 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-26 | 11.56 | 11.1 | 11.848 | 10.85 | 12,176,569 |
| 2021-02-25 | 12.09 | 11.49 | 12.79 | 11.34 | 11,472,602 |
| 2021-02-24 | 11.81 | 12.01 | 12.17 | 11.5 | 8,219,732 |
| 2021-02-23 | 12.1 | 11.68 | 12.14 | 10.9 | 16,319,686 |
| 2021-02-22 | 13.68 | 12.88 | 13.9 | 12.815 | 10,893,185 |
| 2021-02-19 | 14.07 | 13.84 | 14.37 | 13.7 | 8,916,200 |
| 2021-02-18 | 14.88 | 13.97 | 15.34 | 13.83 | 15,412,472 |
| 2021-02-17 | 13.55 | 15.365 | 15.41 | 13.26 | 17,250,538 |
| 2021-02-16 | 14.52 | 13.78 | 14.95 | 13.58 | 17,421,686 |
| 2021-02-15 | 15.42 | 14.22 | 16.08 | 14.18 | 46,247,952 |
| 2021-02-12 | 15.42 | 14.22 | 16.08 | 14.18 | 46,008,687 |
| 2021-02-11 | 13.07 | 13 | 13.39 | 12.71 | 8,645,677 |
| 2021-02-10 | 13.73 | 12.98 | 14.03 | 12.85 | 8,820,399 |
| 2021-02-09 | 13.89 | 13.78 | 14.01 | 13.1411 | 9,124,443 |
| 2021-02-08 | 13 | 13.87 | 14.35 | 12.6 | 17,506,755 |
| 2021-02-05 | 13.17 | 12.835 | 13.39 | 12.51 | 11,898,345 |
| 2021-02-04 | 14.58 | 12.595 | 14.58 | 12.11 | 18,703,172 |
| 2021-02-03 | 14.73 | 14.56 | 15.01 | 13.66 | 22,682,569 |
| 2021-02-02 | 18.97 | 15.09 | 19 | 13.82 | 47,398,834 |
| 2021-02-01 | 13.76 | 16.96 | 18.2 | 13.3 | 93,939,094 |
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries and breakthroughs in oncology, especially those targeting glioblastoma —the most common and aggress...
-
Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions QIAGEN’s bioinformatic expertise raises predictive biomarker power in INOVIO’s patient selectio...
-
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia - Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alter...